GBL is set to invest €0.5bn of equity to acquire a co-controlling minority stake in Rayner from CVC Capital Partners VIII. GBL will partner with CVC and Rayner’s management team to support Rayner in its international growth ambitions.
Rayner is a manufacturer of ophthalmic medical products. Its portfolio includes monofocal and premium Intraocular Lenses (IOLs), ophthalmic consumables including OMIDRIA® and Ophteis OVDs, the SOPHI Phaco platform and a suite of digital tools designed to improve su...
Continue Reading
Sign up for FREE to read the full article and access 128K+ alternative investment headlines.